SCHEMBL4690943

SCHEMBL4690943

CC(C)c1ccc(S(=O)(=O)Nc2ccc(N3CCN(C)CC3)nc2)cc1

nearest known ligand 0.79

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.79
GAA P10253 3/20 0.58
MEN1 O00255 1/20 0.58
HTR6 P50406 1/20 0.58
KDM4E B2RXH2 1/20 0.55
MLNR O43193 1/20 0.48
PANK3 Q9H999 4/20 0.48
RAB9A P51151 2/20 0.47
ALDH1A1 P00352 2/20 0.47
TRIM24 O15164 1/20 0.47
BRD1 O95696 1/20 0.47
BRPF1 P55201 1/20 0.47
DRD2 P14416 1/20 0.47
DRD3 P35462 1/20 0.47
KCNH2 Q12809 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4686816 0.88 KMT2A (1.00) KMT2AGAAMEN1HTR6KDM4E
SCHEMBL15061265 0.88 KMT2A (0.61) KMT2AGAAMEN1HTR6KDM4E
SCHEMBL4686763 0.87 KMT2A (0.60) KMT2AGAAMEN1HTR6KDM4E
SCHEMBL4689169 0.87 KMT2A (0.80) KMT2AGAAMEN1KDM4EMLNR
Hydrochloric Acid SCHEMBL4690768 0.87 KMT2A (0.60) KMT2AGAAMEN1HTR6KDM4E
SCHEMBL15061407 0.87 KMT2A (0.60) KMT2AGAAMEN1HTR6KDM4E
SCHEMBL15061257 0.86 KMT2A (0.60) KMT2AGAAMEN1HTR6KDM4E
Hydrochloric Acid SCHEMBL4686761 0.86 KMT2A (0.59) KMT2AGAAMEN1HTR6KDM4E
SCHEMBL15061200 0.85 KMT2A (0.59) KMT2AGAAMEN1HTR6KDM4E
Hydrochloric Acid SCHEMBL4686777 0.85 KMT2A (0.59) KMT2AGAAMEN1HTR6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8476275-B2 N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor ABBOTT GMBH & CO. KG (DE) 2013-07-02 US claimed
US-8476275-B2 N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor ABBOTT GMBH & CO. KG (DE) 2013-07-02 US disclosed
US-20110294817-A1 N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2011-12-01 US disclosed
EP-1613596-B1 N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2008-03-12 EP disclosed
US-7320979-B2 N-[(piperazinyl)hetaryl]arylsulfonamide compounds ABBOTT GMBH & CO. KG. (DE) 2008-01-22 US disclosed
US-20070054918-A1 N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor ABBOTT GMBH & CO. KG (DE) 2007-03-08 US disclosed
US-20060160809-A1 N-[(piperazinyl)hetaryl]arylsulfonamide compounds ABBOTT GMBH & CO. KG. 2006-07-20 US disclosed
US-20040204422-A1 N-[(Piperazinyl)hetaryl]arylsulfonamide compounds ABBOTT GMBH & CO. KG. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204422-A1 N-[(Piperazinyl)hetaryl]arylsulfonamide compounds CBR1, CBR3, CNR2 KMT2A 3994/4885GAA 1351/4885MEN1 3758/4885
US-20110294817-A1 N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR DRD2, DRD3, TACR1 KMT2A 4228/4885GAA 3322/4885MEN1 4535/4885
US-20070054918-A1 N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor PTGDR, TACR1, TACR2 KMT2A 4198/4885GAA 3515/4885MEN1 4241/4885
US-20060160809-A1 N-[(piperazinyl)hetaryl]arylsulfonamide compounds CBR3, CNR2, CNR1 KMT2A 4399/4885GAA 3265/4885MEN1 4319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.